Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 18/20 | 0.66 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203158 | 1.00 | MMP13 (0.66) | MMP13CXCR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6202602 | 0.92 | MMP13 (0.67) | MMP13 | |
| SCHEMBL6204066 | 0.92 | MMP13 (0.67) | MMP13 | |
| SCHEMBL6203518 | 0.92 | MMP13 (0.66) | MMP13NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6203792 | 0.92 | MMP13 (0.66) | MMP13NPC1RAB9A | |
| SCHEMBL6204746 | 0.92 | MMP13 (0.66) | MMP13NPC1RAB9A | |
| SCHEMBL6202983 | 0.92 | MMP13 (0.77) | MMP13CXCR1 | |
| SCHEMBL6202968 | 0.92 | MMP13 (0.66) | MMP13NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6202866 | 0.92 | MMP13 (0.77) | MMP13CXCR1 | |
| SCHEMBL6204230 | 0.92 | MMP13 (0.66) | MMP13NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501834-B1 | TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6916807-B2 | Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1501834-A1 | TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20030225056-A1 | Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003091259-A1 | TRIARYL-OXY-ARYL-SPIRO-PYRIMIDINE-2, 4, 6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225056-A1 | Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, TIMP3, MMP8 | MMP13 15/4885CXCR1 312/4885NPC1 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.